Flagship Pioneering and entered into an agreement with UK-based Cambridge University Health Partners (CUHP) and the Milner Therapeutics Institute (MTI) to advance research and innovation on biotechnology.
The collaboration will allow more than 40 companies in Flagship Pioneering’s ecosystem collaborate with CUHP and MTI and access new science and technologies, clinical translation and trial support, and data assets and biosamples.
It will also open career development opportunities for Cambridge, UK scientists and students with Flagship.
Flagship Pioneering senior partner and UK head Junaid Bajwa said: “Our collaboration with CUHP and MTI blends breakthrough research, clinical trial support, access to data assets, and accelerated talent development.
“Cambridge is one of the centrepieces of the UK’s life sciences ecosystem, and Flagship has already witnessed firsthand how the US and UK Cambridge ecosystems can potentiate each other’s innovations, with the launch last year of our first co-located company, Quotient Therapeutics.
“We are pleased to announce this collaboration with CUHP and MTI roughly one year after opening our new London hub, and we expect to see further momentum in cooperation between the UK’s rich research and life science networks and Flagship and its companies.”
Launched in 2000, Flagship supports development of bioplatform companies. It has incubated more than 100 scientific ventures, generating more than $60bn in aggregate value.
The company will also work with CUHP and MTI to tap new opportunities across other top organisations in the Cambridge, UK life sciences ecosystem, including the Wellcome Sanger Institute, the University of Cambridge, and the NIHR Cambridge Biomedical Research Centre among others.
Milner Therapeutics Institute director Tony Kouzarides said: “Research collaborations like this can further propel the UK’s position as a hub for biotechnology innovation.”
